Wellbeing Digital Sciences Inc. (“Wellbeing” or the
“Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an
evidence-based healthcare company focused on innovative clinical
solutions, artificial intelligence-powered digital therapeutics and
contract research, is pleased to announce that a clinical study
conducted by its wholly owned subsidiary, KGK Science Inc.
(“
KGK”) for The Beachbody Company (NYSE: BODY)
regarding its superfood nutrition shake named Shakeology®
(“
Shakeology”) has just been published in the
Journal of Nutrition.
The objective of the Study was to determine if
using Shakeology twice-daily can improve weight loss and metabolic
outcomes in otherwise healthy overweight and obese adults. The
benefits experienced by people in the study align with many years
of the results that Shakeology has delivered to consumers.
Accordingly, the people in the Shakeology group lost more weight,
saw decreases in cholesterol that were already in the normal range
and increases in the metabolic hormone adiponectin than in the
placebo group.
The Study was a 12-week, randomized,
double-blinded and placebo-controlled clinical trial that included
a sample of 206 overweight and obese adults from 4 different
locations in the US and Canada. Participants in the Study were
randomized to consume Shakeology or a calorie-matched placebo 30
minutes before breakfast and lunch, while following a calorie
restricted diet for 12 weeks. The primary outcome of the Study was
weight loss that was significantly greater in the Shakeology group
than in the placebo group.
The strengths of the Study included a large
sample size and the increased weight loss experienced by subjects
over and above the calorie-matched placebo. Greater weight loss
indicated that the benefits of Shakeology do not just stem from its
calories, but also from its additional ingredients including the
protein, fiber, superfood and phytonutrient blends that may
contribute to the benefits that people experience with the product.
The most novel finding from the Study was the increase in the
metabolic hormone, adiponectin, which is produced by adipose tissue
in the body and influences how a person’s body makes, uses and
stores energy.
Management Commentary
Dr. Heather Leidy, a member of The Beachbody
Company Scientific Advisory Board and an Associate Professor in the
Department of Nutrition at the University of Texas at Austin who
collaborated on the study said, “This study illustrated that the
consumption of nutrient-rich protein and fiber shakes, like
Shakeology, can lead to significant weight loss and uniquely
increase the secretion of adiponectin – which is a hormone that, in
essence, supports normal blood sugar levels and cardiovascular
health. Thus, these findings support the inclusion of nutritious
shakes, containing protein and fiber, to promote weight management
and metabolic health.”
Najla Guthrie, President and CEO of KGK, added,
“It was an honour to be engaged by The Beachbody Company to conduct
this clinical study and we are pleased with how it was executed and
the results that it yielded about the Shakeology product for our
client. We look forward to potentially working more with The
Beachbody Company and other such clients in the nutrition industry
that ae interested in learning more about their products,
intellectual property or other topics of study. KGK has a long
history as an independent contract research organization and a
robust pipeline of engagements ahead, as the economic rebound from
the COVID-19 pandemic continues to deliver new clients and projects
to our company.”
ABOUT THE BEACHBODY COMPANY,
INC.
Headquartered in Southern California, The
Beachbody Company is a worldwide leading digital fitness and
nutrition subscription company, with over two decades of creating
innovative content and powerful brands. The Beachbody Company is
the parent company to the Beachbody On Demand streaming platform
(BOD) with over 100 complete fitness programs, 4,500 individual
workouts, multiple nutrition programs, and the connected Beachbody
Bike by MYXfitness. For more information, please
visit TheBeachbodyCompany.com.
ABOUT KGK SCIENCE
Founded in 1997, KGK is a leading North American
contract research organization based in London, Ontario that
primarily provides high-quality clinical research trials with a
focus on the nutraceutical and emerging health care products. The
business has successfully helped hundreds of companies with custom
designed clinical trials and claim substantiation strategies to
move products into global markets. KGK’s other existing service
lines include expert regulatory support and compliance solutions,
participant recruitment, research support services and consulting
services. On an approximate basis, the business to date has
produced 150 publications, executed over 400 clinical trials across
more than 40 indications, amassed 25,000 participants in its
database and collected 10 million data points.
ABOUT WELLBEING DIGITAL
SCIENCES
Wellbeing Digital Sciences Inc. is an
evidence-based healthcare company focused on innovative clinical
solutions, artificial intelligence-powered digital therapeutics and
contract research. Its mission is supported by a network of North
American clinics that provide ketamine-assisted therapies and other
types of treatment to patients as well as through a contract
research organization that offers clinical trials services to
clients pursuing drug development. In essence, the company exists
to make breakthrough treatments more accessible and to offer
patients transformational experiences.
On behalf of:
WELLBEING DIGITAL SCIENCES
INC.
"Adam Deffett"Adam Deffett, Interim CEO
For further information, please contact:
Nick Kuzyk, Investor RelationsTel:
1-844-746-6351Email: ir@wellbeingdigital.co Web:
www.wellbeingdigital.coTwitter: @Wellbeing_IR
Notice Regarding Forward-Looking
Information:
This news release contains forward-looking
statements including but not limited to statements regarding the
Company’s business, assets or investments, as well other statements
that are not historical facts. Readers are cautioned not to place
undue reliance on forward-looking statements, as there can be no
assurance that the plans, intentions or expectations upon which
they are based will occur. By their nature, forward-looking
statements involve numerous assumptions, known and unknown risks
and uncertainties, both general and specific, that contribute to
the possibility that the predictions, forecasts, projections and
other forward-looking statements will not occur, which may cause
actual performance and results in future periods to differ
materially from any estimates or projections of future performance
or results expressed or implied by such forward-looking statements.
These assumptions, risks and uncertainties include, among other
things, the state of the economy in general and capital markets in
particular, investor interest in the business and prospects of the
Company.
The forward-looking statements contained in this
news release are made as of the date of this news release. Except
as required by law, the Company disclaims any intention and assumes
no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable securities law. Additionally, the
Company undertakes no obligation to comment on the expectations of,
or statements made, by third parties in respect of the matters
discussed above.
SOURCE: WELLBEING DIGITAL SCIENCES INC.
Beachbody (NYSE:BODY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Beachbody (NYSE:BODY)
Historical Stock Chart
From Apr 2023 to Apr 2024